CRISPR Therapeutics (CRSP) PT Raised to $51 at Citi
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $60.90 +6.69%
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 18
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 18
Join SI Premium – FREE
Citi raised its price target on CRISPR Therapeutics (NASDAQ: CRSP) to $51.00 (from $20.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calumet Specialty Products Partners (CLMT) PT Raised to $47 at UBS
- CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens
- Snowflake Inc. (SNOW) PT Raised to $360 at Benchmark Into Q2 Earnings
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
